Colorectal cancer is highly treatable when caught early—and FIT tests make screening easier than ever with a simple at‑home ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

Of the 9989 participants who could be evaluated, 65 (0.7%) had colorectal cancer and 757 (7.6%) had advanced precancerous lesions (advanced adenomas or sessile serrated polyps measuring ≥1 cm in the ...

Colon cancer is the second-deadliest cancer in the US, partly due to low screening rates. New and emerging screening tools, like blood and breath tests, may offer alternatives to in-office screenings.

An investigational multitarget stool DNA test for screening colorectal cancer detects significantly more cancers than the currently available fecal immunochemical test (FIT), researchers report. But ...

England’s National Health Service’s (NHS') fecal immunochemical test (FIT) has reduced referrals for suspected bowel cancer by 140,000, while the number of cancer cases has remained stable. This shows ...